Abraham Lieberman
Parkinson's disease, dementia with Lewy bodies, pure autonomic failure, and multiple system atrophy are all alpha-synucleinopathies. These are all progressive neurodegenerative disorders marked by abnormal misfolding and buildup of the protein alpha-synuclein (syn) in brain neurons, axons, and glial cells, as well as other organs. After a central nervous system lesion, Neurogenic Bowel Dysfunction (NBD) refers to bowel dysfunction caused by a loss of neurological control. Bowel symptoms such as bowel obstructions, constipation, stomach discomfort, and edoema are prevalent. Passive immunotherapy, on the other hand, has been shown to be safe in clinical studies but less successful than in preclinical circumstances. The present state of passive immunotherapy in animal models of synucleinopathies is discussed. Several studies have shown that manual treatments, such as Osteopathic Manipulative Treatment (OMT), can help with NBD. Focusing treatment on body-first synucleinopathies, when brain damage is still restricted and successful vaccination might potentially stop disease development by preventing pathogenic syn from spreading from peripheral organs to the brain, could perhaps stop disease progression. The goal of this study was to evaluate the effects of OMT on NBD in people with SCI to a Manual Placebo Treatment (MPT). The study was a three-part, doubleblind, randomised controlled experiment with each phase lasting 30 days. Focusing treatment on body-first synucleinopathies, when brain damage is still restricted and successful vaccination might potentially stop disease development by preventing pathogenic syn from spreading from peripheral organs to the brain, could perhaps stop disease progression.